La aspergilosis invasora

Invasive aspergillosis is one of the most frequent fungal infections in neutropenic patients, in whom it is associated with a high mortality. Its diagnosis is difficult by the traditionally used laboratory tests. In the last years, an ELISA (Platelia® Aspergillus, Bio-Rad, France) to detect galactomannan in neutropenic and cancer patients with high risk of suffering invasive aspergillosis has been developed. The experience accumulated in Spain in the diagnosis of invasive aspergillosis by Platelia® Aspergillus is presented in this monograph.

[1]  J. Latgé,et al.  Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis , 1996, European Journal of Clinical Microbiology and Infectious Diseases.

[2]  H. Fricker-Hidalgo,et al.  Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis , 2003, Journal of Clinical Microbiology.

[3]  C. Cordonnier,et al.  Real-Time PCR Coupled with Automated DNA Extraction and Detection of Galactomannan Antigen in Serum by Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis , 2002, Journal of Clinical Microbiology.

[4]  J. Bergerat,et al.  Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Stevens.  Diagnosis of fungal infections: current status. , 2002, The Journal of antimicrobial chemotherapy.

[6]  J. Perfect,et al.  The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Verhaegen,et al.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.

[8]  H. Prentice,et al.  Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.

[9]  N. Singh.  Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Denning,et al.  Analysis of definitions used in clinical research on invasive fungal infections Consensus proposal for new, standardized definitions , 1999 .